12 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
Monash University (Parkville Campus)
Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins.
University of Minnesota
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
Monash University
Discovery of Highly Potent, Selective, and Liver-Targeting HSD17B13 Inhibitor with Robust In Vivo Anti-MASH Activity.
Guangdong Pharmaceutical University
Discovery of First-in-Class FXR and HSD17B13 Dual Modulator for the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease.
Guangdong Pharmaceutical University
Dual Modulator of FXR and HSD17B13: Revitalizing FXR Therapies in MASH.
The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning
Design, synthesis, and biological evaluation of novel highly selective non-carboxylic acid FABP1 inhibitors.
Guangdong Pharmaceutical University
Design, synthesis, and biological evaluation of first-in-class FABP1 inhibitors for the treatment of NASH.
Guangdong Pharmaceutical University
Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease.
Guangdong Pharmaceutical University
Identification and Investigation of Novel Binding Fragments in the Fatty Acid Binding Protein 6 (FABP6).
Takeda Cambridge
Synthesizing Selective Agonists for the ?7 Nicotinic Receptor with in situ Click-Chemistry on Acetylcholine Binding Protein Templates.
University of California San Diego